SpiderRock Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

SpiderRock Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.1M	Sell	2,000 -400	-17%	-$445K	0.03%	315
2024 Q2	$2.52M	Sell	2,400 -100	-4%	-$96.9K	0.05%	237
2024 Q1	$2.4M	Buy	+2,500	New	+$2.38M	0.06%	227
2023 Q4	–	Hold	0	–	–	–	67
2023 Q3	–	Hold	0	–	–	–	55
2023 Q2	–	Hold	0	–	–	–	50
2023 Q1	–	Hold	0	–	–	–	52
2022 Q4	–	Hold	0	–	–	–	50
2022 Q3	–	Hold	0	–	–	–	47
2022 Q2	–	Hold	0	–	–	–	42
2017 Q4	–	Hold	0	–	-$113K	–	322
2017 Q3	–	Hold	0	–	–	–	130
2017 Q2	–	Hold	0	–	–	–	246
2017 Q1	–	Hold	0	–	–	–	172

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SpiderRock Advisors's REGN Position: Q3 2024 in Review

SpiderRock Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 7.2% in Q3 2024, buying an estimated $279K and bringing the position to 3,758 shares worth $3.95M. The position accounts for 0.06% of the portfolio, ranked #197.

SpiderRock Advisors first reported a position in REGN in Q1 2024 and has held it in 3 quarters since. 1,388 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

SpiderRock Advisors held 3,758 shares of Regeneron Pharmaceuticals worth $3.95M as of Q3 2024.
SpiderRock Advisors bought 251 Regeneron Pharmaceuticals shares in Q3 2024, an estimated $279K.
Regeneron Pharmaceuticals made up 0.06% of SpiderRock Advisors's portfolio in Q3 2024, its #197 holding.
SpiderRock Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on SpiderRock Advisors's 13F filing for Q3 2024, filed 1 Nov 2024.